An object of the present invention is to provide a novel compound which has a potent inhibitory effect on FXa and exhibits an excellent antithrombotic effect when orally administered. The present invention provides a compound represented by the following general formula (1): wherein R1 and R2 each independently represent a hydrogen atom, a hydroxy group, an alkyl group or an alkoxy group; Q1 represents a saturated or unsaturated bicyclic or tricyclic fused hydrocarbon group which may be substituted, a saturated or unsaturated bicyclic or tricyclic fused heterocyclic group which may be substituted, or the like; Q2 represents a single bond, a straight-chained or branched alkylene group having 1 to 6 carbon atoms, a straight-chained or branched alkenylene group having 2 to 6 carbon atoms, or the like; R3 and R4 each represent an alkyl group, or the like; m and n each represent an integer from 0 to 3; Q4 represents an aryl group; and T0 and T1 each represent a carbonyl group or the like, and a medicine containing the compound.